论文部分内容阅读
目的 探讨CD44V6、V7/ 8与非小细胞肺癌 (Non smallcelllungcancer ,NSCLC)患者的淋巴结转移及预后的关系。方法 采用免疫组化方法观察CD44V6、V7/ 8在 76例原发性非小细胞肺癌组织及转移淋巴结中的表达。结果 在肺癌中CD44V6、V7/ 8表达鳞癌多于腺癌 (P <0 .0 1) ;在正常肺组织中无表达。淋巴结转移病例中CD44V63 3/36 (91% )表达阳性 ,在 2 5例转移淋巴结中 2 4例表达阳性 (96 % )。CD44V6在Ⅲ～Ⅳ期患者表达高于Ⅰ～Ⅱ期患者 (P <0 .0 1)。结论 肺癌组织CD44V6阳性表达对肿癌的组织病理分型、淋巴结转移及临床分期方面有一定的指导意义。
Objective To investigate the relationship between CD44V6, V7 / 8 and lymph node metastasis and prognosis in patients with non small cell lung cancer (NSCLC). Methods The expressions of CD44V6 and V7 / 8 in 76 cases of primary non-small cell lung cancer and metastatic lymph nodes were observed by immunohistochemistry. Results In lung cancer, CD44V6 and V7 / 8 expressed more squamous cell carcinoma than adenocarcinoma (P <0.01), but no expression in normal lung tissue. CD44V63 3/36 (91%) was positive in lymph node metastases, and 24 (25%) was positive in 25 lymph node metastases (96%). CD44V6 was higher in stage Ⅲ ~ Ⅳ patients than in stage Ⅰ ~ Ⅱ patients (P <0.01). Conclusion The positive expression of CD44V6 in lung cancer has some guiding significance in the histopathological classification, lymph node metastasis and clinical stage of the cancer.